Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/481

AZT transplacental carcinogenesis study: Target Organs and Levels of Evidence for TR-522

Toxicology and Carcinogenesis Studies of Transplacental AZT (CASRN 30516-87-1) in Swiss (CD-1®) Mice (in utero Studies)

Chemical (Study Title)
CASRN
Peer Review DateRoute/Exposure LevelsStudy Laboratory
AZT transplacental carcinogenesis study
30516-87-1
12/09/2004In Utero
AZT: 50, 100, 200, OR 300 MG/KG/DAY; 25, 25, 36, OR 46 PER GROUP
Southern Research Institute

Levels of Evidence

Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Lung: ALVEOLAR/BRONCHIOLAR CARCINOMA 5/50 11/50 6/50 11/37 8/32 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 14/50 20/50 13/50 18/37 18/32
Female Mice: No Evidence